Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus Letrozole in Recurrent HR+/HER2- Gynecologic Solid Tumors
NCT06243185Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in ovarian cancer, uterine cancer. Started Nov 2023; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
ovarian canceruterine cancer
Beyond the preview
Go deeper on NCT06243185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06243185.